In addition, several Nb-based therapeutic agents against TNF-α, IL17A (26), VEGF/angiopoietin-2 (Ang-2) (27), CXCR1, CXCR2 (28), vWF (29), RANKL (30) applicable in autoimmune disease, malignant disease, inflammation, hematopoitic disorders, and bone disorder, respectively, are at various stages of clinical trials. The gene discussed is ANGPT2; the disease is autoimmune disease.